Structure

InChI Key LDDHMLJTFXJGPI-UHFFFAOYSA-N
Smile CC12CC3CC(C)(C1)CC(N)(C3)C2.Cl
InChI
InChI=1S/C12H21N.ClH/c1-10-3-9-4-11(2,6-10)8-12(13,5-9)7-10;/h9H,3-8,13H2,1-2H3;1H

Physicochemical Descriptors

Property Name Value
Molecular Formula C12H22ClN
Molecular Weight 215.77
AlogP 2.69
Hydrogen Bond Acceptor 1.0
Hydrogen Bond Donor 1.0
Number of Rotational Bond 0.0
Polar Surface Area 26.02
Molecular species BASE
Aromatic Rings 0.0
Heavy Atoms 13.0

Pharmacology

Action Mechanism of Action Reference
NEGATIVE ALLOSTERIC MODULATOR Glutamate [NMDA] receptor negative allosteric modulator FDA Wikipedia

Indications

Mesh Heading Maximum Phase Mesh ID Reference
Autistic Disorder 3 D001321 ClinicalTrials
Brain Neoplasms 3 D001932 ClinicalTrials
Frontotemporal Dementia 3 D057180 ClinicalTrials
Learning Disabilities 3 D007859 ClinicalTrials
Amyotrophic Lateral Sclerosis 2 D000690 ClinicalTrials
Anemia, Sickle Cell 2 D000755 ClinicalTrials
Asperger Syndrome 2 D020817 ClinicalTrials
Gambling 2 D005715 ClinicalTrials
Influenza, Human 1 D007251 ClinicalTrials
Gliosarcoma 1 D018316 ClinicalTrials
Hematoma, Subdural, Intracranial 0 D046648 ClinicalTrials
Glioma 0 D005910 ClinicalTrials

Related Entries

Parent
Mixture

Adverse Reactions

System Organ Classification (SOC)
Relative Frequency (%)
Nervous system disorders
22.46
Psychiatric disorders
18.12
General disorders and administration site conditions
11.52
Injury, poisoning and procedural complications
8.36
Cardiac disorders
5.19
Vascular disorders
5.16
Gastrointestinal disorders
4.69
Musculoskeletal and connective tissue disorders
3.63
Respiratory, thoracic and mediastinal disorders
3.34
Investigations
2.85
Metabolism and nutrition disorders
2.61
Renal and urinary disorders
2.35
Skin and subcutaneous tissue disorders
2.27
Infections and infestations
2.01

Cross References

Resources Reference
ChEBI 64323
ChEMBL CHEMBL1699
FDA SRS JY0WD0UA60
Guide to Pharmacology 4253
KEGG C13736
PubChem 181458
SureChEMBL SCHEMBL3053
ZINC ZINC12402582